NSE: LUPIN · 7 October 2026
- Lupin Limited shares moved lower today, trading down by 0.81% to close at ₹2012.90 compared to the previous close of ₹2029.30. The stock moved within a daily range of ₹2001.60 and ₹2030.00, opening slightly lower at ₹2028.30.
- Lupin announced the commercial launch of Formoflo-G® MDI in India following approval from the Drug Controller General of India. It is positioned as the world's first fixed-dose triple combination metered-dose inhaler combining Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for moderate to severe COPD. The therapy targets an estimated 55 million COPD patients in India, strengthening the company's established #2 ranking in the domestic respiratory segment.
- Trading volume was 1.18 times the 20-day average daily volume.
Why is LUPIN share price falling on 7 October 2026?
Lupin Limited shares moved lower today, trading down by 0.81% to close at ₹2012.90 compared to the previous close of ₹2029.30. The stock moved within a daily range of ₹2001.60 and ₹2030.00, opening slightly lower at ₹2028.30.
The broader market exhibited negative momentum, with the benchmark Nifty declining by 0.76%. Sector performance was similarly subdued, as the Nifty Pharma index slipped 0.43%. Lupin's modest decline sits in line with the broader sector correction and general market weakness, while short-term returns show a 5-day decline of 1.91% and a 20-day drawdown of 4.36%.
Company-specific news flow includes a recent press release dated October 06, 2026, announcing the launch of Formoflo-G® MDI in India, recognized as the world's first fixed-dose triple combination drug for COPD management following DCGI approval. Additional recent developments include a tentative U.S. FDA approval for Apixaban Oral Suspension on September 28, 2026, and full ownership consolidation of Multicare Pharmaceuticals Philippines effective October 01, 2026. However, these operational updates did not provide an immediate upward catalyst, as the stock drifted lower alongside broader pharmaceutical and market indices.
7.85 lakh shares traded by 7 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 6.66 lakh shares (1.18 times). The five-day average daily volume was 8.98 lakh shares. Separately, the NSE report for 6 October 2026 showed 7.38 lakh shares delivered, representing 69.19% of that day’s traded volume. The same report recorded 46,799 trades.
The 0.81% decline in Lupin shares lacks a direct negative company catalyst and appears consistent with general market weakness and minor profit-taking following recent consolidation. Broader sector benchmarks also traded lower, aligning the stock's movement with the Nifty Pharma trend.
Latest Company Developments
Lupin announced the commercial launch of Formoflo-G® MDI in India following approval from the Drug Controller General of India. It is positioned as the world's first fixed-dose triple combination metered-dose inhaler combining Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for moderate to severe COPD. The therapy targets an estimated 55 million COPD patients in India, strengthening the company's established #2 ranking in the domestic respiratory segment.
Expands Lupin's domestic specialty portfolio in a core chronic therapeutic area.
Lupin received tentative approval from the U.S. FDA for its New Drug Application for Apixaban Oral Suspension 1.25 mg/mL under the 505(b)(2) pathway. The product serves as an alternative oral liquid formulation to Bristol Myers Squibb's Eliquis®, designed for adult patients requiring anticoagulation therapy who have difficulty swallowing tablets. Upon final approval, manufacturing will be handled at the company's Somerset, New Jersey facility.
Strengthens the U.S. specialty pipeline with a differentiated patient-centric formulation.
Multicare Pharmaceuticals Philippines, Inc. completed the buyback of 30,559 shares, concluding a process initiated earlier in July 2026. Following the transaction, Multicare became a wholly owned subsidiary of Nanomi B.V. and a step-down wholly owned subsidiary of Lupin Limited effective October 01, 2026. This administrative consolidation simplifies the regional corporate structure.
Deepens operational ownership and control within the Southeast Asian regional footprint.
a press release dated October 06, 2026, titled "Lupin Launches Formoflo-G® MDI, World s First Fixed-dose Triple Combination Drug for COPD Management".
a press release dated August 06, 2026, titled "Lupin Q1 FY2027 Results ".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.84% on 30 June 2026. This compares with 16.93% on 31 March 2026, a change of -2.09 percentage points.
The filing reported 39 MF/UTI holders.
Historical Bulk / Block Deals
Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal. Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal Moneycontrol.com
What to Watch Next
- Execution and market uptake of the newly launched Formoflo-G® MDI in the Indian respiratory segment
- Final U.S. FDA approval timelines for Apixaban Oral Suspension from the Somerset facility
- Volume trends and cash delivery percentages relative to the 20-day average volume baseline
- Performance of the Nifty Pharma index and broader market risk sentiment
Other Dated Coverage
More LUPIN news and dated analysis →
Frequently Asked Questions
What is the latest LUPIN company news?
Lupin announced the commercial launch of Formoflo-G® MDI in India following approval from the Drug Controller General of India. It is positioned as the world's first fixed-dose triple combination metered-dose inhaler combining Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for moderate to severe COPD. The therapy targets an estimated 55 million COPD patients in India, strengthening the company's established #2 ranking in the domestic respiratory segment.
How strong was LUPIN’s trading volume?
7.85 lakh shares traded, 1.18 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.